← Library
Insulin Lispro
FDA ApprovedSince 1996
Also known as Humalog, Admelog
Function
Primary
Type 1 Diabetes · Type 2 Diabetes
Mechanism
Rapid-acting insulin analog — binds insulin receptor to facilitate glucose uptake into muscle and fat; suppresses hepatic glucose output.
Evidence
Clinical RCT (Phase III)
Research
Multiple Phase III trials
Dosing
Range
Individualized (units/kg)
Frequency
With meals (rapid-acting)
Route
Subcutaneous · Intravenous
Cycling
Continuous individualized dosing with meals; no cycling.
Benefits
- ·Rapid postprandial glucose control
- ·Flexible meal timing
- ·Reduced late-postprandial hypoglycemia vs regular insulin
Risks
- ·Hypoglycemia
- ·Hypokalemia
- ·Lipodystrophy at injection sites
- ·Weight gain
Contraindications
- ·Hypoglycemia at time of administration
- ·Hypersensitivity to insulin lispro
Regulatory
FDA-Approved Rx
Functional Groups
Cited Works
- Eli Lilly. Humalog (insulin lispro) Prescribing Information.source